Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
Heat shock protein 90 (Hsp90) is a chemical in the body that is involved in the promotion of
cancer. SNX-5422 is an experimental drug that blocks Hsp90.